These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 34591258)

  • 41. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
    Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
    Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Epidemiologic Trends, Global Shifts in Meningococcal Vaccination Guidelines, and Data Supporting the Use of MenACWY-TT Vaccine: A Review.
    Presa J; Findlow J; Vojicic J; Williams S; Serra L
    Infect Dis Ther; 2019 Sep; 8(3):307-333. PubMed ID: 31347097
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of MenACWY-CRM in adolescents in the United States.
    Black S; Block SL
    J Adolesc Health; 2013 Mar; 52(3):271-7. PubMed ID: 23299001
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antibody persistence after primary and booster doses of a quadrivalent meningococcal conjugate vaccine in adolescents.
    Baxter R; Reisinger K; Block SL; Percell S; Odrljin T; Dull PM; Smolenov I
    Pediatr Infect Dis J; 2014 Nov; 33(11):1169-76. PubMed ID: 24911896
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents.
    Jacobson RM; Jackson LA; Reisinger K; Izu A; Odrljin T; Dull PM
    Pediatr Infect Dis J; 2013 Apr; 32(4):e170-7. PubMed ID: 23114372
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Randomized trial to assess the immunogenicity, safety and antibody persistence up to three years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers.
    Vesikari T; Forstén A; Boutriau D; Bianco V; Van der Wielen M; Miller JM
    Hum Vaccin Immunother; 2012 Dec; 8(12):1892-903. PubMed ID: 23032159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America.
    Stamboulian D; Lopardo G; Lopez P; Cortes-Barbosa C; Valencia A; Bedell L; Karsten A; Dull PM
    Int J Infect Dis; 2010 Oct; 14(10):e868-75. PubMed ID: 20655261
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and immunogenicity of an investigational meningococcal ACWY conjugate vaccine (MenACWY-CRM) in healthy Indian subjects aged 2 to 75 years.
    Lalwani S; Agarkhedkar S; Gogtay N; Palkar S; Agarkhedkar S; Thatte U; Vakil H; Jonnalagedda R; Pedotti P; Hoyle M; Bhusal C; Arora A
    Int J Infect Dis; 2015 Sep; 38():36-42. PubMed ID: 26166699
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial.
    Snape MD; Perrett KP; Ford KJ; John TM; Pace D; Yu LM; Langley JM; McNeil S; Dull PM; Ceddia F; Anemona A; Halperin SA; Dobson S; Pollard AJ
    JAMA; 2008 Jan; 299(2):173-84. PubMed ID: 18182599
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel quadrivalent meningococcal A, C, W-135 and Y glycoconjugate vaccine for the broader protection of adolescents and adults.
    Pace D
    Future Microbiol; 2010 Nov; 5(11):1629-40. PubMed ID: 21133685
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Safety and immunogenicity of meningococcal ACWY CRM197-conjugate vaccine in children, adolescents and adults in Russia.
    Ilyina N; Kharit S; Namazova-Baranova L; Asatryan A; Benashvili M; Tkhostova E; Bhusal C; Arora AK
    Hum Vaccin Immunother; 2014; 10(8):2471-81. PubMed ID: 25424958
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of meningococcal ACWY conjugate vaccines on pharyngeal carriage in adolescents: evidence for herd protection from the UK MenACWY programme.
    Carr JP; MacLennan JM; Plested E; Bratcher HB; Harrison OB; Aley PK; Bray JE; Camara S; Rodrigues CMC; Davis K; Bartolf A; Baxter D; Cameron JC; Cunningham R; Faust SN; Fidler K; Gowda R; Heath PT; Hughes S; Khajuria S; Orr D; Raman M; Smith A; Turner DPJ; Whittaker E; Williams CJ; Zipitis CS; Pollard AJ; Oliver J; Morales-Aza B; Lekshmi A; Clark SA; Borrow R; Christensen H; Trotter C; Finn A; Maiden MC; Snape MD;
    Clin Microbiol Infect; 2022 Dec; 28(12):1649.e1-1649.e8. PubMed ID: 35840033
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety and immunogenicity of typhoid fever and yellow fever vaccines when administered concomitantly with quadrivalent meningococcal ACWY glycoconjugate vaccine in healthy adults.
    Alberer M; Burchard G; Jelinek T; Reisinger E; Beran J; Hlavata LC; Forleo-Neto E; Dagnew AF; Arora AK
    J Travel Med; 2015; 22(1):48-56. PubMed ID: 25308927
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age.
    Nolan TM; Nissen MD; Naz A; Shepard J; Bedell L; Hohenboken M; Odrljin T; Dull PM
    Hum Vaccin Immunother; 2014; 10(2):280-9. PubMed ID: 24220326
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune Responses to Booster Vaccination With Meningococcal ABCWY Vaccine After Primary Vaccination With Either Investigational or Licensed Vaccines: A Phase 2 Randomized Study.
    Szenborn L; Block SL; Jackowska T; Konior R; D'Agostino D; Smolenov I; Toneatto D; Welsch JA
    Pediatr Infect Dis J; 2018 May; 37(5):475-482. PubMed ID: 29329168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Summary of the National Advisory Committee on Immunization's Update on quadrivalent meningococcal vaccines available in Canada.
    Henry B;
    Can Commun Dis Rep; 2015 Apr; 41(Suppl 3):17-18. PubMed ID: 29769963
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age.
    Halperin SA; Gupta A; Jeanfreau R; Klein NP; Reisinger K; Walter E; Bedell L; Gill C; Dull PM
    Vaccine; 2010 Nov; 28(50):7865-72. PubMed ID: 20943209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparative Assessment of a Single Dose and a 2-dose Vaccination Series of a Quadrivalent Meningococcal CRM-conjugate Vaccine (MenACWY-CRM) in Children 2-10 Years of Age.
    Johnston W; Essink B; Kirstein J; Forleo-Neto E; Percell S; Han L; Keshavan P; Smolenov I
    Pediatr Infect Dis J; 2016 Jan; 35(1):e19-27. PubMed ID: 26398741
    [TBL] [Abstract][Full Text] [Related]  

  • 59. MenACWY-TT vaccine for active immunization against invasive meningococcal disease.
    Papaevangelou V; Spyridis N
    Expert Rev Vaccines; 2012 May; 11(5):523-37. PubMed ID: 22827239
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antibody persistence 5 years after vaccination at 2 to 10 years of age with Quadrivalent MenACWY-CRM conjugate vaccine, and responses to a booster vaccination.
    Block SL; Christensen S; Verma B; Xie F; Keshavan P; Dull PM; Smolenov I
    Vaccine; 2015 Apr; 33(18):2175-82. PubMed ID: 25744224
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.